Navigation Links
Pfizer joins open-access medicinal chemistry public-private collaboration
Date:6/10/2010

The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors "chemical probes" for proteins involved in epigenetic signalling.

Pfizer and GlaxoSmithKline (GSK) are now members of this collaboration, launched in late 2008 with the aim to provide the community with high quality research reagents, free from restriction on use.

Globally the collaboration includes the three SGC laboratories in Oxford, Toronto and Stockholm, the National Institutes of Health Chemical Genomics Center in Bethesda, the Departments of Chemistry and Biochemistry at the University of Oxford, the Department of Chemistry at Ume University and a number of additional collaborators in academia. The program has been awarded a total of US $15M in grant support from the Wellcome Trust, the Ontario Ministry of Research and Innovation in Canada and the Swedish Foundation for Strategic Research to support activities in the UK, Canada and Sweden, respectively.

The collaboration aims to develop small molecules that can stimulate or block the activity of proteins involved in epigenetic control. The study of epigenetics addresses heritable changes in gene function that occur without a change in the DNA sequence. Alterations in these processes are linked to many common diseases, and there is a strong belief that a better understanding of epigenetics could eventually lead to treatments for diseases such as cancer, diabetes, obesity and many psychiatric diseases. Epigenetics is an area of biology that is poorly understood and the availability of chemical probes should dramatically increase our understanding; some of these probes may also be starting points for drug discovery.

Pfizer is joining the program after having formalized an agreement with the University of Oxford, SGC and GSK. Pfizer will, like GSK, provide medicinal chemistry support to the project. The collaboration is special in that it brings the medicinal chemistry expertise within industry together with the biological expertise within academia to address an emerging area of biology. The ability to add extra industrial members further demonstrates this consortium as a potential working model for pre-competitive interactions between academia and industry within the field of medicinal chemistry.

In keeping with SGC policy, the structure and function of each probe will be made freely available.

Dr Tony Wood, Vice President and Heads of Worldwide Medicinal Chemistry at Pfizer, said: "This collaboration exemplifies our thinking with respect to public-private collaboration that facilitate 'blue sky' research between industry and academia. It is hoped that combining forces in this way will lead to the rapid development and deployment of research tools. This should help us understand the role that this important group of gene families play in human disease and should aid the overarching goal of providing effective medicines to patients."

Dr Aled Edwards, the SGC Chief Executive, adds: "The problem we are tackling together is too big for any single laboratory or organization. We are thrilled that to have two leaders in pharmaceutical research and medicinal chemistry in this global project, and are delighted at this opportunity to collaborate with some of the top medicinal chemists in the world."


'/>"/>

Contact: Johan Weigelt
johan.weigelt@ki.se
46-702-630-255
Wellcome Trust
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Pfizer: Glaucoma - The Sneak Thief of Sight
2. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
3. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
4. Luckey & Mullins Joins with Other National Construction Defect Law Firms to Form Chinese Drywall Legal Network
5. The Chicago Office of McDonald Hopkins Continues to Expand: Healthcare Attorney, Charles F. MacKelvie, Joins the Firms National Healthcare and Healthcare Restructuring Practice Groups
6. Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region
7. CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission
8. Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services
9. Industry Advisor Joins OrthoAccel Technologies, Inc.
10. Worlds #1 Health Brand for Kids Joins Forces With Worlds #1 In-School Childrens Theatre
11. Oncology Industry Veteran, Joe Baffone, Joins onPoint Oncology, LLC.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... ... is scheduled on July 25-27, 2016 at Las Vegas. It aims to bring ... from educational institutes and research organizations across the globe; making the conference a ...
(Date:5/4/2016)... ... ... Netc , a leading provider of barcode and RFID labels ... enables Netc to continue to grow its label business, customer base and market share. ... ability to print and label tape media on site and on an as needed basis. ...
(Date:5/3/2016)... ... May 04, 2016 , ... An accurate ... reaching the global health community through expanding activities that embrace training, standards, technology ... the resource-limited countries. , In support of this important work, ASCP ...
(Date:5/3/2016)... ... May 03, 2016 , ... ProIntro Glitch is a set of ... Film Studios’ titles allow users to add a terrifying opener to any video or ... lines and accents. To add greater contrast, all the user has to do is ...
(Date:5/3/2016)... ... , ... In April, Amerec launched a new website designed with optimal user ... steam and sauna solutions. , First, the Amerec website has been redesigned to be ... the site’s features, especially the Steam Builder Tool , to both mobile and ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)... watching a film or TV show in high definition, you may not be familiar with ...  is a renowned authorized reseller of the medical industry,s top brands as well as a ... ... ... Although initially introduced ...
Breaking Medicine Technology: